Disease · MONDO_0018922
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Number of Patients Achieving Transfusion Avoidance From Week 5 to Week 24-Part A | 12 of 16 | 5 of 8 | 24 | NCT05096403 | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Number of Patients Achieving a Response (R) at Week 24 | 8 of 16 | 2 of 8 | 24 | NCT05096403 | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Hemoglobin Levels-Part A | 7 of 16 | 0 of 8 | 24 | NCT05096403 | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Normalization of Markers of Hemolysis (LDH) at Week 24-Part A | 5 of 13 | 1 of 8 | 21 | NCT05096403 | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for LDH Levels-Part A | 6 of 13 | 2 of 8 | 21 | NCT05096403 | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Normalization of Markers of Hemolysis (Haptoglobin) at Week 24-Part A | 4 of 15 | 0 of 6 | 21 | NCT05096403 | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Haptoglobin Levels-Part A | 7 of 15 | 0 of 6 | 21 | NCT05096403 | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Indirect Bilirubin Levels-Part A | 11 of 13 | 1 of 6 | 19 | NCT05096403 | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Normalization of Markers of Hemolysis (Indirect Bilirubin) at Week 24-Part A | 9 of 13 | 1 of 6 | 19 | NCT05096403 | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for ARC Levels-Part A | 9 of 10 | 3 of 8 | 18 | NCT05096403 | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Normalization of Markers of Hemolysis (ARC) at Week 24-Part A | 4 of 10 | 2 of 8 | 18 | NCT05096403 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018922/comparisons